INTRODUCTION
============

Translation of the bicistronic *ATP8/ATP6* mRNA on yeast mitochondrial ribosomes depends on F~1~ ATPase ([@B20]) and at least one transcript-specific translation factor encoded by *ATP22* ([@B27]). Atp22p is one of a large number of translational activators that target mRNAs for subunits of cytochrome oxidase ([@B15]; [@B5]; [@B18]), cytochrome *b* ([@B22]), and Atp9p ([@B6]). These factors are likely to have similar functions related to some general feature of mitochondrial translation. The requirement of F~1~ for translation of *ATP8/ATP6* mRNA achieves two important results. First, it provides a means by which expression of the mitochondrial *ATP6* and *ATP8* genes is coordinated with the availability of F~1~, a product of the nucleocytoplasmic genetic system. Second, translational down-regulation of the *ATP8/ATP6* transcript in the absence of F~1~ prevents accumulation of an Atp6p-Atp9p ring complex capable of equilibrating protons across the inner membrane and discharging the mitochondrial membrane potential ([@B7]).

In an earlier study ([@B20]), we reported that *ATP22*, when present in high copy number, was able to rescue expression in F~1~ mutants of the reporter gene *ARG8^m^* when the latter is substituted for *ATP6* in mitochondrial DNA (mtDNA; [@B25]; [@B3]). Suppression was attributed to enhanced translation of *ARG8^m^/ATP8* mRNA as a result of the high concentration of the messenger-specific translational activator Atp22p. This approach was used in the present study to screen for and characterize other suppressors. The screen enabled us to identify the product of reading frame YJL147c, here named *SMT1* (Suppression of Mitochondrial Translation), as an important component of the regulatory pathway responsible for the F~1~-dependent translation of the *ATP8/ATP6* mRNA. On the basis of the phenotype of an *smt1*-null mutant and the properties of Smt1p, we propose that it functions to maintain the *ATP8/ATP6* mRNA in a translation- mute form under F~1~ limiting conditions.

RESULTS
=======

Suppression of *ATP6* and *ATP8* expression in F~1~ mutants by extragenic mutations
-----------------------------------------------------------------------------------

The translation block of the *ATP8*/*ATP6* mRNA in strains of yeast with mutations in either the α and β subunits of F~1~ or the Atp11p and Atp12p factors that chaperone assembly of F~1~ was previously corroborated in an *arg8* mutants in which either the *ATP6* or *ATP8* coding sequence was replaced by the *ARG8^m^*, a recoded version of the gene for acetylornithine aminotransferase ([@B3]). The arginine requirement for growth in the absence of F~1~ provided a simple means for isolating and identifying extragenic suppressors of the block in *ATP8*/*ATP6* mRNA translation ([@B20]). As shown previously, overexpression of *ATP22*, coding for the translational activator of the *ATP8/ATP6* mRNA, was found to partially rescue the arginine auxotrophy of MR6ΔATP12ΔATP6, an *arg8* and *atp12* double mutant with an *ARG8^m^* substitution for *ATP6* in mitochondrial DNA ([@B20]). The double mutant was also used to screen for extragenic suppressors by selecting for arginine-independent growth on glucose as the carbon source. MR6ΔATP12ΔATP6 spread at high density (∼10^8^ cells) on minimal glucose medium containing all the growth requirements except for arginine yielded 30--50 revertants with different growth properties after incubation of the plates for 1 wk ([Figure 1A](#F1){ref-type="fig"}). The fastest-growing revertants grew almost as well as the parental strain ([Figure 1B](#F1){ref-type="fig"}). Similar results were obtained with a double *arg8*, *atp12* mutant harboring a mitochondrial genome in which *ATP8* was replaced with *ARG8^m^* (unpublished data).

![Expression of the mitochondrial *atp6::ARG8^m^* allele in F~1~ mutants and revertants. (A) aMRSΔATP12ΔATP6 (200 μl) grown to early stationary phase in YPD was spread on minimal glucose medium supplemented with adenine, uracil, and tryptophan. The photograph of the arginine-independent revertant colonies was taken after incubation of the plate at 30°C for 7 d. (B) Serial dilutions of MRS-3A, an *arg8* mutant (top), and *arg8* mutants and revertants with additional mutations in *ATP12* and the mitochondrial *ATP6* genes. The different strains were spotted on minimal glucose medium containing adenine, uracil, tryptophan, with or without arginine. The plates were incubated at 30°C for 2 d. (C) Top, mutant and revertant strains with the indicated genotypes were grown as in B. The ρ^0^ derivative of the revertant aMRSΔATP12/R1 was crossed to the *kar1* strain DFSΔATP6 containing the mitochondrial *atp6::ARG8^m^* mutation (middle) and to the *kar1* DFSΔATP8 containing the *atp8::ARG8^m^* mutation (bottom). Four independent haploid transductants obtained in each transformation were checked for growth in the absence of arginine. (D) The *atp2* and *atp12* mutants aMRSΔATP2 and aMRSΔATP12, respectively, and aMRSΔATP12/R1, the *atp12* mutant with the *smt1-1* suppressor allele of R1, were labeled with \[^35^S\]methionine in vivo as described previously ([@B20]). Total cellular proteins were separated by SDS--PAGE on 12% (top) and 17% polyacrylamide gels (bottom), transferred to nitrocellulose, and exposed to x-ray film. (E) The Δ*arg8* mutant MR6 and the aMRSΔATP12/R1 revertant (Δ*arg8* Δ*atp12 smt1-1*) were spotted on minimal glucose plus the indicated supplements and on rich ethanol/glycerol (YEPG) medium. The plates were incubated for 2 d at 30°C.](919fig1){#F1}

One of the fast-growing revertants (MR6ΔATP12ΔATP6/R1) was analyzed genetically to ascertain whether the suppressor is nuclear or mitochondrial and whether it is dominant or recessive. A cross of a ρ^0^ derivative, MR6ΔATP12ΔATP6ρ^0^, to the revertant produced diploid cells that failed to grow in the absence of arginine, indicative of a recessive nuclear suppressor ([Figure 1C](#F1){ref-type="fig"}). This was confirmed by crosses of the *kar1* strains with either an *atp6*- or an *atp8*-null mutation in mtDNA (DFSΔATP6 or DFKΔATP8, respectively) to the ρ^0^ derivative of the R1 revertant. Haploid transductants issued from the two crosses were verified to grow in the absence of arginine ([Figure 1C](#F1){ref-type="fig"}). The suppressor of the R1 revertant was also tested directly for restoration of translation of the *ATP8/ATP6* mRNA in an F~1~ mutant background. Translation of the two proteins was assayed in vivo in the *atp12*-null mutant and in the ρ^0^ derivative of the R1 revertant repopulated with wild-type mtDNA. The translational defect of the *ATP8/ATP6* mRNA, previously shown to be elicited by the *atp12* mutation ([@B20]), was largely restored in the revertant containing wild-type mtDNA ([Figure 1D](#F1){ref-type="fig"}). As expected, revertants with a normal mitochondrial genome were auxotrophic for arginine ([Figure 1E](#F1){ref-type="fig"}) and did not grow on rich ethanol/glycerol (YEPG) because of impaired F~1~ assembly in the *atp12* mutant ([@B1]).

Cloning of *SMT1*
-----------------

To clone the recessive suppressor, we transformed MR6ΔATP12ΔATP6/R1 with a library of yeast genomic DNA in the episomal plasmid YEp24 ([@B4]). Approximately 1500 transformants were plated on 10 minimal glucose plates containing all the growth requirements of this strain plus arginine. After replication of the transformants on minimal glucose medium lacking arginine, those found to be auxotrophic for arginine were further checked for plasmid-dependent loss of growth in arginine-deficient medium. Of the several dozen putative arginine auxotrophs, only a few survived this second screen. The plasmid DNA isolated from the R1 revertant strain was determined to have a nuclear DNA insert of ∼8.8 kb from chromosome X ([Figure 2A](#F2){ref-type="fig"}). Suppression of growth in arginine-less medium was mapped to a region of the insert between the *Pst*I and *Nhe*I sites and (pSMT1/ST9 in [Figure 2A](#F2){ref-type="fig"}). This region contained reading frame YJL147c, reported to code for a nonessential protein associated with mitochondrial ribosomes ([@B11]). A null allele of the YJL147c reading frame, henceforth referred to as *SMT1* (Suppression of mitochondrial translation), was constructed by replacing the 492 nucleotides between the internal *Eco*RI and *Hin*dIII sites with a 1-kb fragment containing the yeast *URA3* gene. This plasmid was used to replace wild-type *SMT1* of W303 with the *smt1::URA3* null allele by homologous recombination ([@B21]). Uracil-independent clones were verified by PCR amplification of the *SMT1* locus to have the null allele. The *smt1*-null mutants grew as well as the parental wild-type strains on rich ethanol/glycerol medium (YEPG; [Figure 2B](#F2){ref-type="fig"}, top). Deletion of *SMT1* restored translation of the bicistronic *ATP8/ATP6* mRNA in the F~1~ mutant ([Figure 2, B and C](#F2){ref-type="fig"}). It is interesting that the *smt1*-null mutants displayed an increased synthesis of Atp6p, as evidenced by the accumulation of the unprocessed protein with its presequence (pre-Atp6p in [Figure 2C](#F2){ref-type="fig"}). The identity of this band was confirmed by transformation of the *smt1* mutant with a high-copy plasmid containing *ATP23*, the gene for the protease that processes the precursor ([@B28]; [@B17]). The resultant transformants displayed only mature Atp6p ([Figure 2C](#F2){ref-type="fig"}, right).

![Suppression of the *ATP6* mRNA translation defect by an *smt1*-null mutation. (A) Restriction map of the plasmid isolated from the R1 revertant (pSMT1/T1). Only the locations of the *Eco*RI (E), *Hin*dIII (H), *Bcl*I (Bc), *Nhe*I (Nh), and *Pst*I (P) sites in the inset are shown. The bars labeled ST1 and ST2 correspond to the regions of T1 subcloned in YIp351. The bar labeled ST9 represent the region isolated by colony hybridization of the plasmid library constructed from nuclear DNA of the R1 revertant. All three subclones contained wild-type *SMT1* (clear bar). The map of the *smt1*-null allele is shown above the subclones. (B) Suppression of the *ARG8^m^* expression by an *smt1*-null mutation. Top, the parental W303-1A and the *smt1*-null mutants in opposite mating types were serially diluted, spotted on rich glucose (YPD) and glycerol/ethanol (YEPG) media, and incubated for 2 d at 30°C. Middle and bottom, MRS-3B (Δ*arg8*) and the *arg8* mutant with the indicated additional mutations were tested for growth on YPD and YEPG as in the top. (C) The parental wild-type strain W303-1A, the *smt1*-null mutants in each mating type, and the *atp1*-null mutant with and without the *smt1*-null mutation were labeled and separated by SDS--PAGE, and the Western lot was exposed to x-rays as in [Figure 1D](#F1){ref-type="fig"}. (D) The revertant aMRSΔATP2ΔATP6/R1 (Δ*atp2 atp6::ARG8^m^*) without and with ectopic *SMT1* was grown in the absence and presence of arginine. All the aMRS strains had the *arg8::HIS3* allele.](919fig2){#F2}

The selection used to clone *SMT1* was based on the recessiveness of the mutation in the revertant. This was confirmed by transforming the R1 revertant with *SMT1* on a high-copy plasmid. Randomly picked transformants harboring wild-type *SMT1* displayed the reappearance of the arginine auxotrophy ([Figure 2D](#F2){ref-type="fig"}).

Is Smt1p the suppressor in the R1 revertant?
--------------------------------------------

Because R1 suppressor and the *smt1*-null mutant are recessive, expression of *ARG8^m^* in a diploid mutant issued from a cross of both strains would be expected only if the two suppressors are allelic. In the complementation test, the diploid cells homozygous for the *atp12* and homothallic *atp6::ARG8^m^* and heterozygous for the *smt1* deletion and *R1* suppressor (MRSΔATP12,ATP6,SMT1/R1) grew in the absence of arginine, indicating that the R1 suppressor is allelic with the *smt1*-null mutation ([Figure 3A](#F3){ref-type="fig"}). Sequencing of PCR-amplified *smt1* in the revertant showed a single base change of a G to a T, converting the glutamic acid codon 251 into a stop codon ([Figure 3B](#F3){ref-type="fig"}). This allele will be referred to as *smt1-1.* No difference was noted in the growth properties of the *smt1*-null mutant, the R1 revertant, and the wild type on rich glucose or ethanol/glycerol medium.

![Allelism test and sequence of the R1 suppressor allele. (A) The indicated strains 1) MRSΔATP12ΔATP6, 2) aMRSΔATP12ΔATP6/R1, 3) aMRSΔATP12ΔATP6/R1ρ^0^, and 4) a/αMRSΔATP12,ATP6,SMT1/R1 were streaked on YPD medium and after 2 d replicated on minimal glucose plus adenine, uracil, and tryptophan with and without arginine. The replicas were incubated for 2 d at 30°C. The plate lacking arginine was copied twice because of some residual growth of MRSΔATP12ΔATP6 after the first replication due to the endogenous arginine from growth in YPD. Right, the pertinent genotypes. (B) Sequence of the *smt1* mutation in the cDNA copied from nuclear DNA of the R1 revertant. The single-base G751T mutation creates an ochre terminator at the glutamic codon 251.](919fig3){#F3}

Localization of Smt1p
---------------------

The *SMT1* gene was modified by in-frame fusion of the terminal codon to a sequence coding for the hemagglutinin tag (HA). This construct was inserted at the *LEU2* locus of the *smt1*-null mutant aW303ΔSMT1. Both the mutant and transformant aW303/SMT1-HA with the *SMT1-HA* allele were respiratory competent. Mitochondria but not the postmitochondrial supernatant fraction of the transformant with the HA-tagged Smt1p, contained a 44-kDa protein detectable with an antibody against the HA tag ([Figure 4A](#F4){ref-type="fig"}). This protein, corresponding to Smt1p-HA, was associated with the membrane fraction after sonic disruption of mitochondria and was not extracted from the membrane with alkaline carbonate, indicating that it is an intrinsic membrane protein ([Figure 4B](#F4){ref-type="fig"}). Smt1p-HA was resistant to digestion with proteinase K in mitoplasts lacking an intact outer membrane. Based on the proteinase K susceptibility of known markers for the intermembrane space (cytochrome *b*~2~), the inner membrane (Sco1p), and the matrix (α-ketoglutarate dehydrogenase complex), Smt1p is an inner membrane protein facing the matrix.

![Localization of Smt1p. (A) aW303/SMT1-HA, containing Smt1p with a C-terminal HA tag, was used to isolate mitochondria (Mit) and the postmitochondrial supernatant fraction (PMS) containing soluble cytosolic proteins. Equivalent amounts of mitochondria (50 μg protein) and the soluble cytosolic protein fraction were separated by SDS--PAGE, transferred to nitrocellulose, and probed first with a monoclonal antibody against the HA and then by a secondary peroxidase-coupled anti-mouse antibody. The antigen--antibody complexes were visualized with the Super Signal Chemiluminescent Substrate Kit (Pierce, Rockford, IL). (B) Mitochondria (Mit), 0.5 ml, at a protein concentration of 10 mg/ml were disrupted by sonic oscillation and centrifuged for 20 min at 70,000 × *g*~av~ into submitochondrial membrane vesicles (SMPs) and the supernatant (Sonic sup.) consisting of soluble proteins of the intermembrane space and matrix. The submitochondrial membranes were suspended in a final volume of 0.5 ml of 0.1 M sodium carbonate and 1 mM PMSF and incubated at 4°C for 30 min. The suspension was centrifuged at 100,000 × *g*~av~ to separate the insoluble intrinsic (C-pellet) from soluble extrinsic proteins (C-sup). Equivalent volumes of each fraction were separated by SDS--PAGE and the Western blot treated as in A. (C) Mitochondria (Mit) were converted into mitoplasts under hypotonic conditions. Both were incubated with and without protease K (Prot. K) as described previously ([@B27]). Samples normalized to 50 μg of starting mitochondrial protein were separated by SDS--PAGE and transferred to nitrocellulose. The Western blot was probed with a primary monoclonal antibody against the HA tag to detect Smt1p-HA and with rabbit polyclonal antibodies against the indicated mitochondrial protein markers. Antigen--antibody complexes were visualized as in A, except that the mitochondrial makers were detected with a peroxidase-coupled anti-rabbit antibody.](919fig4){#F4}

Purification and sedimentation properties of Smt1p-CH
-----------------------------------------------------

Our failure to purify Smt1p from cells containing the protein with a single polyhistidine tag prompted us to further modify *SMT1* by inserting between the end of the gene and the histidine codons a short sequence coding for the protein C epitope ([@B14]). This new construct was integrated at the *LEU2* locus of the *smt1*-null mutant. The *SMT1-CH* gene in the resultant strain aW303/SMT1-CH was verified to retain its ability to suppress translation of the ATP8/ATP6 mRNA in F~1~ mutants. Transformation of the Arg+ R1 revertant with integrative plasmids containing either the wild-type (pSMT1/ST19) or the modified (pSMT1/ST18) gene in both cases conferred an arginine-dependent growth phenotype on the revertant ([Figure 5A](#F5){ref-type="fig"}).

![(A) Suppression by *SMT1-CH* of Atp6p translational in the R1 revertant. 1) R1 aMRSΔATP12ΔATP6/R1, 2) aMRSΔATP12ATP6, 3) aMRSΔATP12ATP6/R1/ST18, and 4) aMRSΔATP12ATP6/R1/ST19. The YPD master plate of each strain was replicated and grown on minimal glucose medium plus and minus arginine as in [Figure 3A](#F3){ref-type="fig"}. Left, the pertinent genotypes. (B) Smt1p-CH was purified by the two-step affinity protocol described in *Materials and Methods*. The different fractions at the indicated concentration relative to the starting volume of mitochondria were separated by SDS--PAGE on a 12% polyacrylamide gel and probed as in [Figure 4](#F4){ref-type="fig"}A, except that the primary monoclonal antibody was against the polyhistidine tag. Mitochondria (M), lauryl maltoside extract (Ex), pellet after lauryl maltoside extraction (P), the protein fraction of nonadsorbed proteins on Ni-NTA (Ni-NTA FT), high-imidazole washes of Ni-NTA beads (E1, E2), nonadsorbed proteins on the protein C antibody beads (P-C FT), and three sequential EDTA eluates of the P-C beads (C1, C2, C3). Most of the Smt1-CH was eluted in the first high-imidazole wash and in the first two EDTA eluates from the protein C beads. (C) Fractions E1 and E2 (Ni-NTA) and C1 and C2 (P-C) were combined and separated as in A. The amount of each fraction loaded relative to the starting volume of mitochondria is indicated at the top of each lane. The gel was stained with Coomassie blue. (D) The combined EDTA eluates (C1 and C2) from the P-C beads were separated as in A and either silver stained (Ag) or transferred to nitrocellulose and visualized with a primary antibody against the polyhistidine tag. (E) Top, the EDTA eluate from the P-C beads was mixed with lactate dehydrogenase (LD) and hemoglobin (HGB) and applied to a linear 10--25% sucrose gradient containing in 10 mM Tris-Cl, pH 7.5, 0.1 M NaCl, and 0.1% lauryl maltoside. The gradient was centrifuged at 60,000 rpm in a Beckman 60SW rotor at 4°C for 6 h, and 13 fractions were collected from the bottom of the tube. Each fraction was assayed for lactate dehydrogenase (solid dots) and hemoglobin (open dots). Each fraction was also probed for Smt1p-CH as described in B. Bottom, same as before, except that a strain expressing HA-tagged Smt1p was used and the gradient was loaded with a lauryl maltoside extract of mitochondria without affinity purification. The primary antibody was a monoclonal directed against the HA tag. The peak fractions of lactate dehydrogenase (140 kDa) and hemoglobin (65 kDa) are indicated by the arrows.](919fig5){#F5}

Mitochondria of aW303/SMT1-CH were used to purify the protein from a lauryl maltoside extract by two sequential affinity steps. Most of the protein was recovered in the lauryl maltoside extract and was adsorbed on both the nickel--nitriloacetic acid (Ni-NTA) and the protein C antibody--coated beads from which it was eluted under nondenaturing conditions in the presence of EDTA ([Figure 5B](#F5){ref-type="fig"}). The elution fraction obtained by this procedure consisted predominantly of a major product that migrated as a 44-kDa protein and of a less abundant product slightly smaller in size ([Figure 5, C and D](#F5){ref-type="fig"}). Mass spectrophotometric analysis of the two bands confirmed both to be Smt1p-CH. The shorter and less abundant protein may be the product of alternate processing of the N-terminal extension in the precursor during its import into mitochondria or of a proteinase-sensitive site cleaved during the purification.

The size of purified Smt1p was assessed by sedimentation of the fraction eluted from the P-C antibody beads in sucrose gradients. The protein peaked at a position of the gradient intermediate between the hemoglobin and lactate dehydrogenase size standards, with an estimated mass of 80--90 kDa corresponding an Smt1p dimer ([Figure 5E](#F5){ref-type="fig"}, top). Similar results were obtained with a crude lauryl maltoside extract from a strain expressing HA-tagged Smt1p analyzed under similar conditions ([Figure 5E](#F5){ref-type="fig"}, bottom).

Detection of Smt1p-*ATP8/ATP6* mRNA complex
-------------------------------------------

Restoration of the *ATP6* and *ATP8* expression in F~1~ mutants lacking Smt1p suggested that the latter might be a repressor that modulates translation of the *ATP8/ATP6* mRNA ([Figure 6A](#F6){ref-type="fig"}) in response to the demand of Atp8p and Atp6p for assembly with F~1~ and other protein constituents of the ATP synthase. The proposed function of Smt1p as a translational repressor implies its interaction with the target RNA. The existence of such a complex was tested in aW303ΔNUC1/SMT1-CH, a strain containing Smt1p double tagged with a protein C and polyhistidine and having a null mutation in *NUC1*, which codes for an abundant nuclease of yeast mitochondria ([@B26]). The *nuc1* mutation did not abolish but did substantially reduce the loss of mitochondrial RNA after their extraction with digitonin ([Figure 6B](#F6){ref-type="fig"}). The procedure used to assess association of *ATP8/ATP6* mRNA with Smt1p-CH ([Figure 6C](#F6){ref-type="fig"}) entailed extraction of mitochondria with digitonin followed by affinity purification of Smt1p in the extract on protein C antibody beads and reverse transcription PCR (RT-PCR) amplification with primers specific for *ATP8/ATP6* mRNA ([Figure 6D](#F6){ref-type="fig"}).

![Detection of Smt1p-*ATP8/ATP6* transcript in mitochondria. (A) Map of the *ATP8/ATP6* mRNA. The *ATP8* and *ATP6* genes are denoted by the solid bars. The locations of the RT and PCR primers are shown by the arrows. (B) Stabilization of mitochondria RNAs in digitonin extracts of mitochondria from yeast with a Δ*nuc1* mutation. Mitochondria (Mito) from the Δ*nuc1* mutant W303ΔNUC1 were extracted with phenol and nucleic acids, precipitated with ethanol, and separated on a 1% agarose gel, without treatment and after digestion with *Mse*I restriction endonuclease to digest DNA and with RNase I to digest RNA. Mitochondria were extracted with 2% digitonin and treated identically. The two mitochondrial ribosomal RNAs and DNA are identified in the margin. (C) Outline of protocol used to purify the Smt1p-CH-*ATP8/ATP6* mRNA complex. (D) Smt1p was purified from 25 μg of starting mitochondria, separated by SDS--PAGE, and probed as in [Figure 4](#F4){ref-type="fig"}A, except that the primary antibody was against the polyhistidine tag. The fractions shown are mitochondria (M), digitonin extract (Ex), the fraction that did not adsorb to the protein C antibody beads (FT), and eluate from the beads (EL). The samples loaded were normalized to the starting volume of mitochondria. (E) Detection of an *ATP8/ATP6* cDNA after RT-PCR amplification of the fraction enriched on protein C antibody beads. Left, each lane of the gel was loaded with the PCR product obtained from the equivalent of 25 μg of starting mitochondrial protein from aW303ΔNUC1 (*SMT1* Δ*nuc1*) and aW303ΔNUC1/SMT1-CH (*SMT1-CH Δnuc1*). The mitochondria were extracted with 2% digitonin, and the extract was purified on beads as described in *Materials and Methods*. One-half of the nucleic acids extracted from protein C eluate was either reverse transcribed (+RT) prior to PCR amplification or directly PCR amplified (--RT). The product shown in the extreme right lane was obtained with Atp6-29 and Atp6-24 PCR primers using purified mitochondrial DNA as the template. Right, same as the left, except that the mitochondria were aW303ΔNUC1/SMT1-CH (*SMT1-CH Δnuc1*) and aW303ΔNUC1/LAT1-CH (*LAT1-CH Δnuc1*), a strain that expresses the dihydrolipoamide acetyltransferase component (E2) of pyruvate dehydrogenase with a CH tag. (F) Effect on cDNA synthesis of addition of mitochondrial RNA from MR10 to the protein C eluate. The conditions for purification and RT-PCR amplification were the same as in E. The indicated amounts of purified total RNA from MR10 (*atp6::ARG8^m^*) were added to the nucleic acids extracted from the protein C antibody beads. The purified RNA (10 μg) was also used directly as the template for PCR amplification either without or with prior reverse transcription. A faint product was obtained in both conditions. The origin of this product is not known.](919fig6){#F6}

PCR amplification of mitochondrial DNA produced a product of ∼1.2 kb, consistent with the expected size of the *ATP8/ATP6* mRNA based on the locations of the two primers. A cDNA product of the same size was also detected after RT-PCR amplification of nucleic acids in the protein fraction purified on the protein C beads ([Figure 6E](#F6){ref-type="fig"}). This cDNA was confirmed by sequencing to span the sequence of the *ATP8/ATP6* locus between the two primers. The product with the *ATP8/ATP6* sequence depended on a prior treatment of the fraction with reverse transcriptase, indicating that the cDNA was copied from RNA. The 1.2-kb product was not observed with mitochondria from a strain with the *nuc1* mutation but with untagged Smt1p ([Figure 6E](#F6){ref-type="fig"}, left) or mitochondria from a strain expressing C-terminal CH tag fused to dihydrolipoamide acetyltransferase component of pyruvate dehydrogenase complex, encoded by *LAT1*, used as a negative control ([Figure 6E](#F6){ref-type="fig"}, middle).

Additional evidence excluding the presence of the *ATP8/ATP6* transcript due to nonspecific binding of RNA to the beads was excluded by lack of competition when excess yeast RNA purified from the *atp6*-null mutant MR10 was added to the extract ([Figure 6F](#F6){ref-type="fig"}). Addition of this RNA increased the amount of final *ATP8/ATP6* cDNA as a result of more efficient precipitation of the cDNA in the presence of the MR10 RNA.

The specificity of Smt1p for mitochondrial transcripts was also examined by testing its ability to bind the mRNA for the *COB*, *COX3*, and *ATP9* for the cytochrome *b* subunit of the bc1 complex, subunit 3 of cytochrome oxidase, and subunit 9 of the ATP synthase, respectively. The primers internal to the *COB* coding sequence ([Figure 7A](#F7){ref-type="fig"}) were verified to amplify the gene from mitochondrial DNA ([Figure 7B](#F7){ref-type="fig"}). The *COB* primers also amplified a product of the right size and sequence from the RNA in the Smt1p-CH purified fraction. This product depended on the inclusion of a reverse transcriptase step before PCR amplification ([Figure 7C](#F7){ref-type="fig"}) and was not seen in the *nuc1*-null mutant with the normal *SMT1* gene ([Figure 7C](#F7){ref-type="fig"}). The results obtained with PCR primers spanning the *COX3* and *ATP9* coding sequences could not be interpreted. Even though these primers amplified single bands of the right size with mitochondrial DNA as template, the smeared products obtained with the *nuc1*-negative control and with purified Smt1p-CH precluded an answer as to whether they are also associated with Smt1p.

![Presence of *COB* mRNA in purified Smt1p-CH. (A) The locations of primers used for RT-PCR amplification of *COB* mRNA are shown by the arrows. (B) PCR amplification of *COB* from mtDNA of the intronless strain MRSI^o^. (C) Smt1p was purified from digitonin extracts of mitochondria from the control strain W303ΔNUC1 with unmodified *SMT1* (*SMT1 Δnuc1*) and from aW303ΔNUC1/SMT1-CH (*SMT1-CH Δnuc1*) as described in the legend to [Figure 6, C and E](#F6){ref-type="fig"}. The eluate from the protein C antibody beads was further processed as in [Figure 6E](#F6){ref-type="fig"}.](919fig7){#F7}

The *ATP8/ATP6* and *COB* mRNAs were also detected in Smt1p purified by the procedure using lauryl maltoside instead of digitonin and including purification on Ni-NTA before the protein C antibody beads (unpublished data).

DISCUSSION
==========

In this study, we used genetic and biochemical means to gain additional mechanistic details underlying the previously observed F~1~-dependent translation of the *ATP8/ATP6* mRNA ([@B20]). Using a double *arg8* and *atp12* (F~1~ chaperone) mutant with a substitution of the mitochondrial *ATP6* gene by recoded *ARG8^m^* for acetylornithine transaminase synthesis on mitochondrial ribosomes ([@B25]), we obtained a number of arginine-independent revertants. The R1 revertant reported here grew as well as wild type in the absence of arginine and was ascertained to have a recessive mutation in a nuclear gene. The recessive nature of the suppressor was taken advantage of to isolate *SMT1*, which, when mutated, confers arginine- independent growth and, like the suppressor in R1, is also recessive. Sequencing of the *SMT1* in the R1 revertant indicated that the suppressor mutation creates a premature termination codon in the gene. Allelism of the R1 suppressor with the *smt1*-null mutation was also confirmed genetically.

Smt1p sedimented approximately midway between lactate dehydrogenase and hemoglobin, suggesting a size two times larger than the monomer estimated by SDS--PAGE. Smt1p behaves as an intrinsic inner membrane protein facing the matrix compartment.

A requisite for the proposed function of Smt1p as a translational repressor is that it interacts with the *ATP8/ATP6* mRNA. The presence of the *ATP8/ATP6* mRNA was confirmed by PCR amplification of a reverse transcriptase--dependent cDNA product obtained with *ATP8* and *ATP6* primers when the template was extracted from Smt1p-CH purified on protein C antibody beads in the presence of digitonin or lauryl maltoside. On the basis of our genetic and biochemical results, we propose that the previously observed F~1~-dependent regulation of Atp6p and Atp8p synthesis involves a mechanism at the core of which activation of *ATP8/ATP6* mRNA translation is prevented by repressor proteins. A second important feature of this model is the labilization of the repressor-*ATP8/ATP6* mRNA complex by F~1~, allowing Atp22p to exercise its function as a translational activator ([Figure 8](#F8){ref-type="fig"}). This would imply a common or overlapping binding site on the mRNA for Atp22p and Smt1p.

![Model of *ATP8/ATP6* mRNA translational regulation by F~1~. In the absence of F~1~, the *ATP8/ATP6* mRNA is associated with Smt1p. When bound to the repressor, the mRNA is prevented from interacting with Atp22p to initiate translation. F~1~ is proposed to weaken the interaction of the repressor with the *ATP8/ATP6* mRNA, thereby allowing Atp22p to bind to the mRNA and activate translation. Based on its sedimentation, native Atp22p, like Smt1p, is a dimer (unpublished data). When overexpressed from *ATP22* on a high-copy plasmid, Atp22p is able to interact with a limited amount of *ATP8/ATP6* mRNA and partially suppress the translational block in the absence of F~1~.](919fig8){#F8}

Of interest, RNA binding by Smt1p is not confined to the *ATP8/ATP6* mRNA. Primers internal to *COB* yielded a PCR product of the right sequence when RNA extracted from purified Smt1p-CH was reverse transcribed and PCR amplified. Smt1p (Mrx5p) was recently reported to be associated with ribosomes in a large complex termed Miorex ([@B10], [@B11]). Purified Smt1p is a single dimeric protein, suggesting that the purification procedure may have led to its dissociation from the Miorex complex. The presence of the *COB* mRNA cannot be explained by the presence of the Miorex complex with both *ATP8/ATP6* and *COB* mRNA, as purified Smt1p-CH consists of a single protein. Instead, it suggests a possible involvement of Smt1p in translational regulation of at least one other mitochondrial gene product.

MATERIALS AND METHODS
=====================

Yeast strains and growth media
------------------------------

The yeast strains used in this study and their genotypes are listed in [Table 1](#T1){ref-type="table"}. The compositions of yeast extract/peptone/glucose (YPD), YP plus ethanol/glycerol, YP plus galactose, and minimal glucose media have been described ([@B16]).

###### 

Genotypes and sources of *Saccharomyces cerevisiae* strains. Continued

  Strain                        Genotype                                                                                                                                                           mtDNA                    Source
  ----------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------ --------------------------------------------------
  W303-1A                       **MAT**a *ade2-1 his3-1,15 leu2-3,112 trp1-1 ura3-1*                                                                                                               ρ^+^                     R. Rothstein (Columbia University, New York, NY)
  W303-1B                       **MAT**α *ade2-1 his3-1,15 leu2-3,112 trp1-1 ura3-1*                                                                                                               ρ^+^                     R. Rothstein
  DFSΔATP6                      **MAT**α *kar1 ade2 leu2 ura3 arg8::URA3*                                                                                                                          ρ^+^ *atp6::ARG8^m^*     This study
  DFKΔATP8                      **MAT**α *kar1 ade2 leu2 lys2 ura3 arg8::URA3*                                                                                                                     ρ^+^ *atp8::ARG8^m^*     This study
  MR6ΔATP6                      **MAT**a *ade2-1 his3-1,15 leu2-3,112 trp1-1 ura3-1 arg8::HIS3*                                                                                                    ρ^+^ *atp6::ARG8^m^*     [@B20])
  MR6ΔATP8                      **MAT**a *ade2-1 his3-1,15 leu2-3,112 trp1-1 ura3-1 arg8::HIS3*                                                                                                    ρ^+^ *atp8::ARG8^m^*     [@B20])
  aW303ΔSMT1                    **MAT**a *ade2-1 his3-1,15 leu2-3,112 smt1::URA3 trp1-1 ura3-1*                                                                                                    ρ^+^                     This study
  W303ΔSMT1                     **MAT**α *ade2-1 his3-1,15 leu2-3,112 smt1::URA3 trp1-1 ura3-1*                                                                                                    ρ^+^                     This study
  aW303/SMT1-HA                 **MAT**a *ade2-1 his3-1,15 leu2-3,112 smt1::URA3 trp1-1 ura3-1 leu2::pSMT1/ST5*                                                                                    ρ^+^                     This study
  aW303/SMT1-CH                 **MAT**a *ade2-1 his3-1,15 leu2-3,112 smt1::URA3 trp1-1 ura3-1 leu2::pSMT1/ST13*                                                                                   ρ^+^                     This study
  aW303/SMT1-CHρ^0^             **MAT**a *ade2-1 his3-1,15 leu2-3,112 smt1::URA3 trp1-1 ura3-1 leu2::pSMT1/ST13*                                                                                   ρ^0^                     This study
  aW303ΔNUC1                    **MAT**a *ade2-1 his3-1,15 leu2-3,112 nuc1::TRP1 trp1-1 ura3-1*                                                                                                    ρ^+^                     This study
  aW303ΔNUC1ΔSMT1               **MAT**a *ade2-1 his3-1,15 leu2-3,112 nuc1::TRP1 smt1::URA3 trp1-1 ura3-1*                                                                                         ρ^+^                     This study
  aW303ΔNUC1/SMT1-CH            **MAT**a *ade2-1 his3-1,15 leu2-3,112 nuc1::TRP1 smt1::URA3trp1-1 ura3-1 leu2::pSMT1/ST13*                                                                         ρ^+^                     This study
  aW303ΔNUC1/LAT1-CH            **MAT**a *ade2-1 his3-1,15 lat1::HIS3 leu2-3,112 nuc1::TRP1 trp1-1 ura3-1 leu2::pLAT1/ST6*                                                                         ρ^+^                     This study
  MR6                           **MAT**a *ade2-1 arg8::HIS3 his3-1,15 leu2-3,112 trp1-1 ura3-1*                                                                                                    ρ^+^                     [@B19]
  MR10                          **MAT**a *ade2-1 arg8::HIS3 his3-1,15 leu2-3,112 trp1-1 ura3-1*                                                                                                    ρ^+^ *atp6::ARG8^m^*     [@B19]
  MRSI^0^                       **MAT**a *ade2-1 arg8::HIS3 his3-1,15 leu2-3,112 trp1-1 ura3-1*                                                                                                    ρ^+^, intronless         [@B20]
  aW303ΔATP1/SMT1-CH            **MAT**a *ade2-1 atp1::HIS3 his3-1,15 leu2-3,112 smt1::URA3 trp1-1 ura3-1 leu2::pSMT1/ST13*                                                                        ρ^+^                     This study
  aW303ΔCOX2/SMT1-CH            **MAT**a *ade2-1 atp1::HIS3 his3-1,15 leu2-3,112 smt1::URA3 trp1-1 ura3-1 leu2::pSMT1/ST13*                                                                        ρ^+^ *cox2*::*ARG8^m^*   This study
  MRS-3A                        **MAT**a *ade2-1 arg8::HIS3 his3-1,15 leu2-3,112 trp1-1 ura3-1*                                                                                                    ρ^+^                     [@B20]
  aMRSΔATP2ΔATP6                **MAT**a *ade2-1arg8::HIS3 atp2::LEU2 his3-1,15 leu2-3,112 trp1-1 ura3-1*                                                                                          ρ^+^ *atp6::ARG8^m^*     [@B20]
  aMRSΔATP2ΔATP6/R1             **MAT**a *ade2-1 arg8::HIS3 atp2::LEU2 his3-1,15 leu2-3,112 smt1-1 trp1-1 ura3-1*                                                                                  ρ^+^ *atp6::ARG8^m^*     This study
  aMRSΔATP12                    **MAT**a *ade2-1 arg8::HIS3 atp12::HIS3 his3-1,15 leu2-3,112 trp1-1 ura3-1*                                                                                        ρ^+^                     [@B20]
  aMRSΔATP12/R1                 **MAT**a *ade2-1 arg8::HIS3 atp12::HIS3 his3-1,15 leu2-3,112 smt1-1 trp1-1 ura3-1*                                                                                 ρ^+^                     This study
  aMRSΔATP12ΔATP6               **MAT**a *ade2-1 arg8::HIS3 atp12::LEU2 his3-1,15 leu2-3,112 trp1-1 ura3-1*                                                                                        ρ^+^ *atp6::ARG8^m^*     [@B20]
  MRSΔATP12ΔATP6                **MAT**α *ade2-1 arg8::HIS3 atp12::LEU2 his3-1,15 leu2-3,112 trp1-1 ura3-1*                                                                                        ρ^+^ *atp6::ARG8^m^*     This study
  aMRSΔATP12ΔATP6/R1            **MAT**a *ade2-1 arg8::HIS3 atp12::LEU2 his3-1,15 leu2-3,112 smt1-1 trp1-1 ura3-1*                                                                                 ρ^+^ *atp6::ARG8^m^*     This study
  aMRSΔATP12ΔATP6/R1ρ^0^        **MAT**a *ade2-1 arg8::HIS3 atp12::LEU2 his3-1,15 leu2-3,112 smt1-1 trp1-1 ura3-1*                                                                                 ρ^0^                     This study
  aMRSΔATP12ΔATP6/R2ρ^0^        **MAT**a *ade2-1 arg8::HIS3 atp12::LEU2 his3-1,15 leu2-3,112 trp1-1 ura3-1 R2sup*                                                                                  ρ^0^ *atp6::ARG8^m^*     This study
  aMRSΔATP12,ATP6//R1/SMT1-CH   **MAT**a *ade2-1 his3-1,15 leu2-3,112 smt1-1 trp1-1 ura3-1 arg8::HIS3 atp12::LEU2 trp1::pSMT1/ST18*                                                                ρ^+^ *atp6::ARG8^m^*     This study
  aMRSΔATP12,ATP6//R1/SMT1      **MAT**a *ade2-1 arg8::HIS3 atp12::LEU2 his3-1,15 leu2-3,112 smt1-1 trp1-1 ura3-1 trp1::pSMT1/ST19*                                                                ρ^+^ *atp6::ARG8^m^*     This study
  a/αMRSΔATP12,ATP6,SMT1/R1     **MAT**a/α *ade2-1/ade2-1 arg8::HIS3/arg8::HIS3 atp12::LEU2/atp12::LEU2 his3-1,15/his3-1,15 leu2-3,112/leu2-3,112 smt1-1/smt1::HIS3 trp1-1/trp1-1 ura3-1/ura3-1*   ρ^+^ *atp6::ARG8^m^*     This study

Construction of the *smt1*-null allele
--------------------------------------

The 3-kb *Bcl*I fragment of pSMT1/T1 containing the entire *SMT1* coding sequence plus 5′ and 3′ flanking sequences was cloned into the *Bam*H1 site of YEp352B, a shuttle plasmid identical to YEp352 ([@B9]) except for the presence of a single *Bam*H1 site instead of the multiple cloning sequence. The resultant plasmid pSMT1/ST2 was digested with *Eco*R1 plus *Hin*dIII to remove 500 base pairs from the middle of the gene. The gapped plasmid was ligated to a 1-kb *Eco*RI-*Hin*dIII fragment containing the yeast *URA3* gene to yield pSMT1/ST3. The *smt1::URA3* allele plus flanking sequences was removed from pSMT1/ST3 as a *Bst*U1-*Nhe*I fragment and was used to transform W303-1A. Several uracil-independent and respiratory-competent clones (aW303ΔSMT1) obtained from the transformation were verified by PCR amplification of the *SMT1* locus to carry the *smt1*-null allele. The alpha mating type *smt1*-null mutant was obtained from a cross of aW303ΔSMT1 to W303-1B.

Construction of yeast strains that synthesize Smt1p with a C-terminal hemagglutinin and a double protein-C plus polyhistidine tag
---------------------------------------------------------------------------------------------------------------------------------

Primers Smt1-1 and Smt1-2 ([Table 2](#T2){ref-type="table"}) were used to amplify *SMT1* fused at the 3′ end with a sequence coding for the HA tag. The PCR product consisting of ∼500 nucleotides of the 5′-untranslated region (5′-UTR), the entire *SMT1* coding sequence fused to the sequence of the tag, was digested with a combination of *Sac*I and *Pst*I and ligated to the YIp351 ([@B9]) linearized with the same enzymes, yielding plasmid pSMT1/ST5. Similarly, primers Smt1-1 and Smt1-3 were used to amplify the 5′-UTR and coding sequence of SMT1 without the termination codon. The PCR product was digested with a combination of *Sac*I and *Pst*1 and ligated to YIp351-CH cut with the same combination of enzymes. The product of this ligation (pSMT1/ST13) resulted in an in-frame ligation of *SMT1* to a sequence coding for the protein C tag followed by three glycines followed by six histidine codons and a TAA terminator. The last codon of *SMT1* was followed by the Leu and Gln codons contributed by the *Pst*I cloning site before the start of the CH tag ([Table 2](#T2){ref-type="table"}). Both pSMT1/ST5 and pSMT1/ST13 were linearized at the *Cla*I site internal to the *LEU2* gene of YIp351. The linear plasmid sequence was integrated at the *leu2* locus of aW303ΔSMT1 ([@B21]) to obtain aW303/SMT1-HA and aW303/SMT1-CH, respectively.

###### 

Sequences of primers and of CH double tag.

  Primer name                                                Primer sequence
  ---------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------
  Primers used for construction of HA- and CH-tagged Smt1p   
  Smt1-1                                                     5′ ggcgagctctgctatcggccgtacatagtaag
  Smt1-2                                                     5′ ggcctgcagtcaagcgtagtctgggacgtcgtatgggtatatgaggttcaatggtaagtg
  Smt1-3                                                     5′ cctgcagtatgaggttcaatggtaagtg
  *ATP8/ATP6* primers                                        
  Atp6-29                                                    5′ cctatgatcttaagattatatgtatctag
  Atp6-24                                                    5′ ggtactaatggtaatggtgtaccagcaggtacg
                                                             *COB* primers
  Cob-20                                                     5′ atggcatttagaaaatcaaatgtg
  Cob-21                                                     5′ ctctaccgatatagaataaaacattttc
  CH double tag                                              CTGCAGGAAGATCAGGTAGATCCACGGTTAATCGATGGTAAGGGAGGAGGACACCATCACCATCATCACTAA LeuGlnGluAspGlnValAspProArgLeuIleAspGlyLysGlyGlyGlyHisHisHisHisHisHisEnd

Purification of Smt1p
---------------------

The procedure of [@B8] was used to prepare mitochondria from aW303/SMT1-CH grown to early stationary phase in YPGal. In a typical purification, 20 ml of the mitochondrial suspension at a protein concentration of 10 mg/ml was adjusted to 2 mM phenylmethanesulfonate fluoride (PMSF) with a 0.2 M ethanolic solution and 1% lauryl maltoside with a 10% solution. After centrifugation at 70,000 × *g*~av~ for 10 min, the supernatant was adjusted to pH 8.2 with 1.5 M Tris-Cl, pH 8.8, and added to 1 ml of packed Ni-NTA beads that had been prewashed with Ni-NTA wash buffer (10 mM Tris-Cl, pH 7.5, 10 mM imidazole, pH 8, 100 mM NaCl). The mixture was rotated at 4°C for 2 h, and nonadsorbed proteins were removed by centrifugation at 1000 rpm for 10 s. The beads were washed three times with 5 ml of Ni-NTA wash buffer containing 0.1% lauryl maltoside and eluted with 2 ml of Ni-NTA elution buffer (10 mM Tris-Cl, pH 7.5, 350 mM imidazole, 100 mM NaCl, 0.1% lauryl maltoside). The eluate from the Ni-NTA beads was adjusted to 2 mM CaCl~2~ and added to 200 ml of packed protein C antibody beads (Anti-Protein C Affinity Matrix; Roche Life Sciences, Indianapolis, IN) that had been prewashed in PC wash buffer (10 mM Tris-Cl, pH 7.5, 2 mM CaCl~2~, 100 mM NaCl, 0.1% lauryl maltoside). After rotation of the mixture for 1.5 h, unadsorbed proteins were removed by centrifugation at 1000 rpm for 10 s, and the beads were washed four times with 1 ml of PC wash buffer. The washed beads were then eluted twice with 100 μl of PC elution buffer (10 mM Tris-Cl, pH 7.5, 7 mM EDTA, 100 mM NaCl, 0.1% lauryl maltoside).

Pull down of Smt1p and RT-PCR amplification of *ATP8/ATP6* cDNA
---------------------------------------------------------------

A mitochondrial suspension representing 250 μg of protein was centrifuged at 10,000 × *g*~av~ for 10 min and used to purify Smt1p as described, with the following modifications. The pellet was extracted in 50 μl of 2% digitonin in PC wash buffer. The digitonin extract was added to 30 μl of packed protein C antibody beads and rotated for 30 min. After four washes of the beads with PC buffer containing 0.5% digitonin, proteins were eluted with 60 μl of PC elution buffer containing 0.5% digitonin.

The eluate was extracted with an equal volume of water-saturated phenol, and nucleic acids were precipitated by addition of 5 M NaCl to a final concentration of 0.25 M and three volumes of ethanol. The pelleted and dried nucleic acid was dissolved in 10 μl of water and reverse transcribed in a final volume of 20 μl with the Atp6-24 primer using the Script cDNA synthesis kit (BioLab). The resultant cDNA was precipitated by addition of salt and ethanol and PCR amplified with primers Atp6-29 and Atp6-24 in a final volume of 50 μl. The cDNA was separated on a 1% agarose gel and visualized by ethidium bromide staining.

Miscellaneous procedures
------------------------

Yeast was transformed by the LiAc procedure of [@B24]. Standard protocols were used for DNA cloning, purification of plasmids from *Escherichia coli*, and colony hybridization ([@B23]). The conditions for in vivo labeling of yeast mitochondrial gene products with \[^35^S\]methionine have been described ([@B20]). Proteins were separated by SDS--PAGE in the buffer system of [@B12]. Protein concentration was determined by the procedure of [@B13].
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EDTA

:   ethylenediaminetetraacetic acid

ρ^−^ mutant

:   respiratory-deficient mutant with partially deleted mitochondrial DNA

ρ^+^ genome

:   wild-type mitochondrial DNA

ρ^0^ mutant

:   respiratory-deficient mutant lacking mitochondrial DNA.
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